Advanced Oncotherapy uses proton beam therapy to target resistant cancers

Panorama of a city business district with office buildings and skyscrapers and superimposed data, charts and diagrams related to stock market, currency exchange and global finance. Blue line graphs with numbers and exchange rates, candlestick charts and financial figures fill the image with a glowing light. Sunset light.
  • Advanced Oncotherapy signs initial deal to provide LIGHT system treatment rooms for GBP75.5mln
  • Proton beam therapy will become as common as MRI scanning believes Advanced Oncotherapy’s chief executive
  • Advanced Oncotherapy builds commercial traction with Saba deal, says research house
  • Advanced Oncotherapy present research potentially offering ‘powerful weapon to resistant cancers’
cancer cell

Quick facts: Advanced Oncotherapy PLC


View company profile

Advanced Oncotherapy is a specialist developer and provider of a breakthrough proton therapy system, the LIGHT system, which is the result of 25 years of work at CERN and ADAM.

The company’s focus is on developing and supplying technologies to maximise the destructive effect of radiation on tumours whilst minimising damage to the patient’s healthy tissues.

03 Jun 2021

() said it signed a letter of intent with Saba Partners for the proposed purchase of a three-treatment room LIGHT system for a total contract value of up to US$107mln (GBP75.5mln).

The AIM-listed firm is a developer of next-generation proton therapy systems for cancer treatment, called LIGHT systems, while Saba is an investment advisory and asset management firm based in Geneva with decades of experience in healthcare services and healthcare real estate.

The contract value reflects the purchase of the LIGHT equipment, its installation and an extended long-term maintenance and warranty agreement, said the healthcare group.

The system will be installed in a proton therapy centre in Glion, Switzerland, where Saba plans to start building a medical centre.

Read more

12 Mar 2021

() told investors it has demonstrated the potential capability and superiority of its LIGHT technology in “biologically enhanced particle therapy” to treat resistant cancers.

This is a group of cancers that are responsible for most relapses and one of the major causes of death in cancer, it noted.

Read more

22 Jan 2021

() said it has raised GBP5.9mln via a share placing at 40p a pop.

The buyers of the new stock, which was priced at just a 2% discount to the group’s average closing price over the past 30 days, were clients of SI Capital, an independent stockbroker.

Read more

09 Aug 2019

Proton therapy, a very precise kind of radiotherapy to treat cancer, has only recently become available to patients in the UK and it is still reserved to a narrow group of patients.

Before joining (), Serandour worked for 15 years as an advisor to some of the largest as well as some of the most innovative healthcare firms and saw first-hand how technologies have changed the healthcare landscape.

Read more

03 Jun 2021

‘s () agreement with Saba Partners, an investment consultant in the Gulf region, potentially opens the door to additional markets, says research house goetzpartners.

The letter of intent announced today relates to a single system to be installed in Glion, Switzerland with a contract value of up to US$107mln (GBP75.5mln).

Goetzpartners, which has a target price of 135p and ‘outperform’ rating, adds it had already factored in deals such as this into its forecasts but with the first operational system now close to completion, commercial traction is now the key driver.

Read more

22 Mar 2021

‘s () Jonathan Farr, Chief Clinical Officer, talks to Proactive London’s Katie Pilbeam about their latest findings in regard to resistant cancers.

The firm recently announced to their investors that it had demonstrated superiority of its LIGHT technology in ‘biologically enhanced particle therapy’ to treat these resistant cancers.

Farr explains, these cancers are responsible for most relapses and one of the major causes of death in cancer.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…


Market Report: Rising oil prices remind investors of the inflation risk brewing

FTSE100 beat a retreat in early trading as rising oil prices reminded investors of the inflation risk brewing. London’s blue-chip index dropped 45 to 7,062.

Adding to the concerns, petrol prices are at a two-year high according to the RAC. A litre now costs129.27p on average, the highest…

17 hours, 12 minutes ago

2 min read


Please enter your comment!
Please enter your name here